STAAR Surgical (STAA) Stock Forecast & Price Target

Staar Surgical Co is well-positioned for robust growth, as the ophthalmic surgical and diagnostic devices market is projected to reach $20.1 billion by 2025, reflecting a steady 2.9% compound annual growth rate since 2019. The company’s implantable Collamer lenses (ICLs) are gaining significant traction, increasing their market share from 14.3% in 2019 to an estimated 26.5% in 2025, driven by strong demand and competitive advantages over traditional laser procedures. Additionally, Staar's reported strong performance in international markets, particularly in China and the Americas, coupled with ongoing expansions in manufacturing, suggest a strengthening revenue trajectory and improved profit margins.

Staar Surgical Co is currently facing significant challenges, evidenced by steep revenue declines, particularly stemming from a catastrophic -82% year-over-year drop in its China revenue during 4Q'24, contributing to broader company losses and strategic uncertainty. The company has reported ongoing EBITDA losses and heavy cash consumption, leaving it unattractive for premium valuations amidst fears of insufficient sustained growth and elevated execution risk. Furthermore, the company’s historical multiples have not recovered to pre-crisis levels, raising concerns over the potential for continued compression or prolonged depression of stock multiples as market sentiment remains cautious regarding the turnaround narrative.